Contact Us

Drug Coated Stents
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 


Cell Phone 

Street Address 

Zip Code 



Which drug-coated stent was implanted?

Date the device was implanted:

Is the device still implanted?

What medical condition prompted the use of the device?

Did you develop blood clotting?

Please describe any problems or injuries caused by the product:

For verification purposes, please answer the below question:

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.

Drug Coated Stents

Drug Coated Stents Side Effects Lawsuits | Side Effects: Blood Clots, Heart Attack, Death | Faulty Device, Defective Medical Equipment

Drug Coated Stents Side Effects May Be Linked To Heart Attack Lawsuits

Drug Coated Stents | Lawsuits, Lawyers | Side Effects: Blood Clots, Heart Attack, Death | Faulty Device, Defective Medical Equipment

Blood Clots Four to Five Times More Likely With Drug Coated Stents Than Older Bare Metal Stents

A study published in the December 2006 issue of the American Journal of Medicine, found that blood clotting is four to five times more likely to occur with the newer drug eluting coronary heart stents than with the older bare metal stents.  The increased risk of blood clotting (thrombosis) is associated with an increased risk of heart attack and death. The two FDA approved drug eluting stents are Johnson & Johnson’s Cypher Stent (emited sirolimus) and Boston Scientific’s Taxus Stent (emits paclitaxel).

As a result of this study, the researchers have recommended that patients with Johnson & Johnson Cypher stents should take anti-clotting drugs for two to three months following implantation, and those patients with the Boston Scientific Taxus stents should take anti-clotting drugs for six months or more following implantation. Anti-clotting or anti-platelet drugs such as Plavix (clopidogrel) and aspirin are often prescribed after the stent procedure.

Drug Coated Stents and Heart Attacks

A second study published in 2007 found that drug coated stents posed a particular risk to patients with a history of heart attacks.  The Drug Coated Stents study, conducted by researchers at the Bichat-Claude Bernard Hospital in Paris, France, analyzed a patient database from 94 hospitals in 14 countries.  The patients involved in this research had heart attacks that had resulted from a blood clot that completely blocked blood flow to the heart – the most damaging type of heart attack.  Patients with the drug coated stents were five times more likely to die than patients who received the bare metal stents.  The researchers hypothesize that heart attack victims might have problems with the drug coated stents because blood vessels narrow following such a cardiac episode.  This can lead to a gap around the stent – an ideal place for a blood clot to form.

Angioplasty Procedure

Drug coated stents were developed to address the problem of restenosis, or reclosure of an artery following angioplasty.  In angioplasty, a balloon is inserted through an incision in the groin or arm and moved to the place of the blockage.  It is inflated in order to expand the opening and allow for more regular blood flow.  Following this, a stent is then inserted through the vessel to the place cleared by the balloon.  The stent holds the artery open, acting as a scaffolding supporting the vessel walls.  With the older bare metal stents, the artery would heal around the device, and the resulting scar tissue would sometimes reblock the artery (restenosis).

Drug coated stents were then developed.  The drugs that are emited from the polymer are intended to suppress the formation of scars and prevent the arteries from closing again. Because the drugs prevent the artery lining from healing around the device, the device creates a location for blood clots to form.  Heart attacks are often the result of blood clots in stent patients.  Other companies, Abbott Laboratories and Medtronic, are developing stents designed to gain a piece of the $6 billion annual stent market.  Stents which dissolve are also under development.

Legal Help for Drug Coated Stent Patients

If you or a loved one suffered blood clotting (thrombosis) after having a drug-eluting stent implanted following angioplasty surgery, you are encouraged to contact Parker & Waichman, LLP for a FREE case evaluation by a qualified defective medical device attorney.  Call 1-800-YOURLAWYER (1-800-968-7529) or fill out our form at the right.

Our defective medical device lawyers are working with patients injured by Boston Scientific TAXUS Express Stents and Johnson Johnson Cypher Stents


Drug Coated StentsRSS Feed

FDA Evaluating Risks of Long-Term Anti-platelet Therapy

Nov 20, 2014
On November 16 the Food and Drug Administration (FDA) announced that it is evaluating preliminary data from a clinical trial showing an increased overall risk of death for patients treated for 30 months with dual anti-platelet blood-thinning therapy (DAPT) compared to 12 months of treatment following the implant of a coronary stent. The FDA is reviewing data from a Harvard Clinical Research Institute study presented at this week’s meeting of the American Heart Association and published...

Medtronic Shares Fall on Questions About Stent

Oct 17, 2008 | Parker Waichman LLP
We have been writing about a number of findings related to stents that were revealed at the Transcatheter Cardiovascular Therapeutics meeting that took place recently in Washington.  Because of the results of one of the studies, entitled Sort Out III, Medronic—a medical device maker—shares fell Thursday.  The study revealed that Medtronic’s new drug-coated stent—the Endeavor—was linked with increased heart attacks and blood clots versus a stent made by...

Senators Probe Industry Ties to Medical Device Conference Organizers

Oct 17, 2008 | Parker Waichman LLP
Two lawmakers have written to the organizers of the Transcatheter Cardiovascular Therapeutics conference in Washington, D.C.  about the financial support they receive from  five medical device companies, including Johnson & Johnson, Medtronic Inc. and Abbott Laboratories.  Senator Charles Grassley (R-Iowa) and Senator Herbert Kohl (D-Wisconsin) have been investigating the financial ties between industry and doctors, and have sponsored legislation that would force drug...

Surgery Deemed More Effective Than Boston Scientifics’ Taxus Stent

Sep 2, 2008 | Parker Waichman LLP
Doctors are now reporting that Boston Scientific Corporation’s Taxus stent did not fare as well as bypass surgery in improving medical outcomes for the sickest patients with a build-up of fatty deposits in their arteries.  After one year, 12.1 percent of bypass patients had died, experienced a heart attack or stroke, or required repeat surgery versus the 17.8 percent of those patients who received a tube—known as a stent—to prop open a clogged artery.  The...

Heart Stents No Better than Drugs in the Long Run

Aug 14, 2008 | Parker Waichman LLP
An international team of researchers just reported in the New England Journal of Medicine that while using drugs alone may take longer than angioplasty or stent surgery to help restore blood flow in patients with clogged arteries, patients fare just as well in the long term.  PCI, or percutaneous coronary intervention, is the surgery that offers increased short-term relief for some patients with severe or more frequent chest pain.  PCI benefits tend to diminish in time according to...

More Drug Coated Stents News

Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo